

CORRECTION

Open Access



Correction to: Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients

Per Nived^{1,2*}, Göran Jönsson³, Bo Settergren¹, Jon Einarsson², Tor Olofsson², Charlotte Sværke Jørgensen⁴, Lillemor Skattum⁵ and Meliha C. Kapetanovic²

Correction to: *Arthritis Res Ther* (2020) 22:36
<https://doi.org/10.1186/s13075-020-2124-3>

Following publication of the original article [1], the authors identified two errors of referencing in the Discussion.

In the first paragraph of the Discussion, previous references 19–21 are incorrectly used twice and should be replaced with new references 36–38 and added to the reference list as follows:

36. Bingham CO, 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. *Arthritis Rheum.* 2010;62(1):64–74.

37. Rehnberg M, Brisslert M, Amu S, Zendjanchi K, Hawi G, Bokarewa MI. Vaccination response to

protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. *Arthritis Res Ther.* 2010;12(3):R111.

38. Crnkic Kapetanovic M, Saxne T, Jonsson G, Truedsson L, Geborek P. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. *Arthritis Res Ther.* 2013;15(5):R171.

In the fifth paragraph, reference 15 is incorrectly used twice, and should be replaced with reference 9.

The authors sincerely apologize to the readers for any confusion caused by the errors.

Author details

¹Department of Infectious Diseases, Central Hospital Kristianstad, J A Hedlunds väg 5, SE-291 85 Kristianstad, Sweden. ²Department of Clinical Sciences Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden. ³Department of Clinical Sciences Lund, Section of Infectious Diseases, Lund University and Skåne University Hospital, Lund, Sweden. ⁴Department of Microbiological Diagnostics & Virology, Statens Serum Institut, Copenhagen, Denmark. ⁵Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund,

The original article can be found online at <https://doi.org/10.1186/s13075-020-2124-3>.

* Correspondence: per.nived@med.lu.se

¹Department of Infectious Diseases, Central Hospital Kristianstad, J A Hedlunds väg 5, SE-291 85 Kristianstad, Sweden

²Department of Clinical Sciences Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

University, Lund and Clinical Immunology and Transfusion Medicine, Region Skåne, Lund, Sweden.

Published online: 26 June 2020

Reference

1. Nived P, Jönsson G, Settergren B, et al. Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients. *Arthritis Res Ther.* 2020;22:36 <https://doi.org/10.1186/s13075-020-2124-3>.